2. Academic Validation
  3. Quercetin alleviates postmenopausal atherosclerosis by suppressing endothelial cell ferroptosis via regulating the KEAP1/NRF2/GPX4 signalling pathway

Quercetin alleviates postmenopausal atherosclerosis by suppressing endothelial cell ferroptosis via regulating the KEAP1/NRF2/GPX4 signalling pathway

  • Br J Pharmacol. 2025 Oct 8. doi: 10.1111/bph.70200.
Ying Lv 1 2 3,  Xiuzhu Weng 4 5,  Yuxiao Zhu 1 2 3,  Xinyi Zhang 1 2 3,  Yue Ma 1 2 3,  Xinyu Dai 1 2 3,  Xiaoxuan Bai 1 2 3,  Shan Zhang 1 2 3,  Jinyu Qi 1 2 3,  Xinxin Zhu 1 2 3,  Yuwu Chen 1 2 3,  Ming Zeng 1 3,  Wei Meng 1,  Qiuwen Wu 1 2 3,  Ji Li 1 2 3,  Haibo Jia 1 2 3,  Bo Yu 1 2 3
Affiliations

Affiliations

  • 1 Department of Cardiology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.
  • 2 Key Laboratory of Myocardial Ischemia, Ministry of Education, Harbin Medical University, Harbin, China.
  • 3 The National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin Medical University, Harbin, China.
  • 4 Department of Cardiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • 5 The Higher Educational Key Laboratory for Cardiovascular Disease of Fujian Province, Clinical Research Center for Metabolic Heart Disease of Fujian Province, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
PMID: 41063334 DOI: 10.1111/bph.70200
Abstract

Background and purpose: Postmenopausal women experience accelerated progression of atherosclerosis, yet the underlying mechanisms remain poorly understood and effective therapeutic strategies are limited. This study aimed to investigate the protective effects of quercetin (QCT) against postmenopausal atherosclerosis and to elucidate its mechanism through the KEAP1/NRF2 pathway-mediated inhibition of endothelial cell Ferroptosis.

Experimental approach: A postmenopausal atherosclerosis model was established using bilateral ovariectomy (OVX) combined with a high-fat diet in apoE-/- female mice. The therapeutic effects of QCT and a Ferroptosis inhibitor Fer-1 were evaluated through histological, biochemical and molecular analyses. For in vitro studies, ox-LDL-induced endothelial cells were conducted to examine the antiferroptosis mechanism of QCT. The role of NRF2 was further validated using AAV-shNRF2 in vivo and ML385 (NRF2 inhibitor) in vitro.

Key results: Both QCT and Fer-1 significantly attenuated postmenopausal atherosclerosis progression, as evidenced by reduced lipid peroxidation, decreased iron deposition and suppressed endothelial cell Ferroptosis in OVX mice. QCT treatment up-regulated GPX4 whilst down-regulating ACSL4 expression and reducing ROS accumulation in ox-LDL-induced endothelial cells. Mechanistically, QCT promoted KEAP1 ubiquitination and subsequent degradation, leading to NRF2 nuclear translocation and activation of downstream antioxidant pathways. The protective effects of QCT were significantly diminished by NRF2 inhibition, both in vitro and in vivo.

Conclusion and implications: This study demonstrates that QCT alleviated postmenopausal atherosclerosis by inhibiting endothelial cell Ferroptosis through KEAP1 ubiquitination-mediated activation of the NRF2/GPX4 pathway. These findings provide novel insights into the molecular mechanisms of postmenopausal atherosclerosis and suggest QCT as a potential therapeutic agent for this condition.

Keywords

KEAP1/NRF2 pathway; atherosclerosis; endothelial dysfunction; ferroptosis; postmenopausal women; quercetin; ubiquitination.

Figures
Products